This transition is tightly regulated by oncogenic drivers such as neuroblastoma-derived MYC (MYCN), which play a pivotal role in reprogramming gene expression and promoting metabolic reorganization to meet the increased biosynthetic demands of aggressive cancer cells [13, 17]. The gene discussed is MYCN; the disease is cancer.